Pharmacotherapy of prostate carcinoma;Medicamenteuze behandeling van prostaatcarcinoom

Nederlands Tijdschrift voor Geneeskunde

Volumn 141, Issue 39, 1997, Pages 1855-1858

  Witjes, J A ^a   Debruyne, F M J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; CYPROTERONE; DIETHYLSTILBESTROL; ESTRAMUSTINE; ESTROGEN; FINASTERIDE; FLUTAMIDE; GONADORELIN; GONADORELIN DERIVATIVE; KETOCONAZOLE; MITOXANTRONE; NILUTAMIDE; STEROID 5ALPHA REDUCTASE INHIBITOR;

DRUG CHOICE; DRUG EFFICACY; DRUG INFORMATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PROSTATE CARCINOMA; RECEPTOR BLOCKING; SHORT SURVEY; SIDE EFFECT;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; ESTROGENS; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS;

EID: 0030772793     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (24)

1. Kiemeney LALM, Witjes JA, Hendrikx AJM, Kil PJM, Vasen HFA. Erfelijk prostaatcarcinoom. Ned Tijdschr Geneeskd 1996;140: 1068-72.
2. Huggins C, Hodges C. Studies on prostate cancer. I. The effect of castration, of estragen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941, 1:293-7.
3. Huggins C, Stevens RE, Hodges CV. Studies on prostate cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 1941:43:209-23.
4. Geller J, Albert JD. DHT in prostate cancer tissue - a guide to management and therapy. Prostate 1985;6:19-25.
5. Huggins C, Scott WW. Bilateral adrenalectomy in prostate cancer. Clinical features and urinary secretion of 17-ketosteroids and estragen. Ann Surg 1945;122:1031-41.
6. Robinson MRG. A further analysis of European Organization for Research and Treatment of Cancer protocol 30805. Orchidectomy versus orchidectomy plus cyproterone acetate versus low-dose diethylstilbestrol. Cancer 1993;72(12 Suppl):3855-7.
7. Veterans Administration Co-operative Urological Research Group. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967;124-1011-7.
8. Kaisary AV, Tyrrell CJ, Peeling WB, Griffiths K. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br J Urol 1991;67:502-8.
9. Labrie F, Dupont A, Belanger A, Cusan L, Lacourciere Y, Monfette G, et al. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 1982;5:267-75.
10. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321 419-24.
11. Denis LJ, Carnelro de Moura JL, Bono A, Sylvester R, Whelan P, Newling D, et al. Goserelin acetate and flutamide versus bilateral orchiectomy: a phase III EORTC trial (30853). EORTC GU Group and EORTC Data Center Urology 1993;42:119-30.
12. Janknegt RA, Abbou CC, Bartoletti R, Bernstein-Hahn L, Bracken B, Brisset JM, et al. Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. J Urol 1993;149:77-83.
13. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Lancet 1995;346: 265-9.
14. Fitzpatrick JM. Combined androgen blockade is the treatment of choice for patients with advanced prostate cancer: the argument against. Eur Urol 1996:29 Suppl 2:37-9.
15. Debruyne FMJ. Combined androgen blockade is the treatment of choice for patients with advanced prostate cancer: the argument for. Eur Urol 1996;29 Suppl 2:34-6.
16. Forman JD, Kumar R, Haas G, Montie J, Porter AT, Mesina CF. Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: effects on the volume of normal tissue irradiation. Cancer Invest 1995;13:8-15.
17. Akakura K, Bruchovsky N, Goldenberg SL, Rennie PS, Buckley AR, Sullivan LD. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer 1993;71:2782-90.
18. Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K. Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology 1995;45:839-45.
19. Fleshner NE, Trachtenberg J. Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects. J Urol 1995;154:1642-6.
20. Kreis W, Budman DR, Calabro A. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br J Urol 1997;79:196-202.
21. Witjes JA, Frenandez del Moral P, Geboers ADH, Beart L, Casselman J, Stagier M, et al. Ketoconazol in hoher Dosierung (HD) zur Behandlung des metastasierten Prostatkarzinoms. Akt Urol 1989;20:29-32.
22. Seidmon EJ, Trump DL, Kreis W, Hall SW, Kurman MR, Ouyang SP, et al. Phase I/II dose-escalation study of liarozole in patients with stage D, hormone-refractory carcinoma of the prostate. Ann Surg Oncol 1995;2:550-6.
23. Perry CM, McTavish D. Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging 1995;7:49-74.
24. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-64